1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Aspira Pathlab & Diagnostics Limited

Aspira Pathlab & Diagnostics Limited

ASPIRA.BO
Aspira Pathlab & Diagnostics LimitedIN flagBombay Stock Exchange
125.50
INR
-2.55
- -
1.29BMarket Cap
Aspira Pathlab & Diagnostics Limited
ASPIRA.BO
(Bombay Stock Exchange)

Recent

price

125.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
- -
- -
- -
- -
1.46
8.39
10.92
9.82
15.97
18.99
14.05
12.83
21.33
- -
24.29
Revenue per Share
0.1
0.01
0.04
0.03
0.04
0.05
-5.25
-10.75
-7.41
-4.95
1.45
4.33
-0.09
-2.6
2.01
- -
0.01
Basic EPS, GAAP
-0.08
-0.03
-0.02
-0.05
0.01
-0.78
-16.2
-11.18
-5.57
-2.23
5.65
1.38
-0.14
0.77
1.49
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.13
1.14
1.18
1.21
4.81
4.87
5.29
-5.46
-7.16
-9.52
-5.93
-1.14
-1.18
-3.71
-1.74
- -
10.01
Book Value per Share
1.13
1.14
1.18
1.21
6.95
7
9.28
-1.38
-3.5
-4.42
0.62
4.96
4.98
2.47
4.43
- -
8.66
Tangible Book Value per Share
5
5
5
5
5
5
5
5
7
9
10
10
10
10
10
- -
10
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
8
44
76
84
152
195
145
132
220
250
250
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-362.04
-114.53
-57.76
-41.37
13.62
25.93
0.08
-20.47
9.23
-0.3
-0.29
Operating Margin (%)
- -
- -
- -
- -
- -
- -
2
11
12
17
14
16
16
15
15
15
15
Depreciation Expense
1
- -
- -
- -
- -
- -
-27
-56
-52
-42
14
45
-1
-27
21
1
- -
Net Income, GAAP
31.08
31.02
34.91
30.9
64.15
25.28
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-359.09
-128.1
-67.86
-50.38
9.08
22.82
-0.61
-20.24
9.42
0.21
0.03
Profit Margin (%)
6
6
6
6
36
31
-18
2
-19
-18
19
54
43
23
30
14
14
Working Capital
- -
- -
- -
- -
- -
- -
32
105
42
45
5
24
17
10
12
24
24
LT Debt
6
6
6
6
36
36
59
3
52
38
83
128
128
101
122
122
122
Total Equity
- -
-1.23
-1.26
-1.74
0.65
-2.7
- -
- -
- -
- -
19.14
40.21
- -
- -
16.31
-0.52
-0.49
Return on Invested Capital (%)
- -
0.94
3.23
2.55
1.49
1.62
- -
- -
- -
- -
77.96
128.43
- -
- -
60.93
4.7
4.23
Return on Capital (%)
- -
0.83
3.23
2.55
1.49
1.09
-103.33
- -
- -
- -
- -
- -
- -
- -
- -
- -
32.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
9
- -
9
LT Borrowings
13
- -
14
LT Finance Leases
10
- -
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
- -
10
Market Capitalization
668
682
575

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
68
- -
46
Cash, Cash Equivalents & STI
19
- -
17
Accounts Receivable, Net
37
- -
17
Inventories
7
- -
7
Total Current Liabilities
29
- -
32
Payables & Accruals
- -
- -
- -
ST Debt
9
- -
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
156.43%
10.71%
0.53%
Free Cash Flow
70.71%
-154.73%
-50.74%
Net Income, GAAP
-732.28%
551.69%
-97.52%
Sales/Revenue/Turnover
- -
14.8%
13.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26
33
35
38
132
2025
46
62
54
58
220
2026
52
81
51
65
250

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.7
-0.69
-0.72
- -
-2.6
2025
0.05
0.96
0.37
0.7
2.01
2026
0.41
1.78
-1.52
-0.67
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Krishna Institute of Medical Sciences Limited (KIMS.NS)
Bangkok Dusit Medical Services Public Company Limited (BDULF)
Numinus Wellness Inc. (NMNSF)
PT Royal Prima Tbk (PRIM.JK)
Nephro Care India Ltd. (NEPHROCARE-ST.NS)
Sienna Senior Living Inc. (LWSCF)
Business
Aspira Pathlab & Diagnostics Limited is a prominent entity in the diagnostic services sector, operating a vast network of diagnostic centers and laboratories across India. The company offers a comprehensive array of medical diagnostic and testing services, encompassing sophisticated pathological investigations such as bio-chemistry, hematology, histopathology, microbiology, immune-chemistry, immunology, virology, and cytology. Beyond pathology, Aspira also provides radiological examinations including X-rays and ultrasound sonography, alongside various cardiology services. With a focus on both individual patient care and corporate wellness, Aspira crafts preventive health packages for diverse age groups, conducts on-site and off-site employee health evaluations, offers industry-specific rapid screening, and manages secure employee health data. Established in 1973, the company prides itself on technological automation and IT integration, aimed at reducing human error and ensuring precise sample tracking. Aspira has expanded its reach significantly, now operating over 600 centers nationwide, with 91 new locations added in the fiscal year 2024-25 alone. Recent financial results indicate a strong performance, with the company reporting a profit of Rs. 2.07 crores for FY 2024-25, a notable improvement from a prior year's loss. Furthermore, for the second quarter ending September 30, 2025, Aspira recorded increased sales of INR 80.93 million and a net income of INR 18.35 million. An open offer was announced on September 26, 2025, by a consortium of acquirers to purchase a 26% stake in the company. Headquartered in Navi Mumbai, India, Aspira reinforces its patient-centric approach through services like home sample collection and its AspiraHealth mobile application, which facilitates appointment booking and access to test results.